Abstract: A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib.

Abstract: A method for preventing and/or treating fibrosis associated with an eye-related disease or disorder includes administering an effective amount of a multikinase inhibitor to a subject in need thereof. The multikinase inhibitor is nintedanib, lenvatinib, a combination thereof, or a salt thereof. The eye-related disease or disorder is corneal transparency, corneal scar formation, secondary cataract formation, glaucoma filtration surgery, ocular surgical procedures and implants, photorefractive keratectomy, laser in situ keratomileusis, formation and contraction of pre- and epiretinal membranes, proliferative vitreoretinopathy, subretinal fibrosis/scarring, retinal gliosis, or formation of choroidal membranes.

Abstract: This disclosure relates to a pharmaceutical bio-dissolvable/bioerodible aqueous gel system optionally comprising an active pharmaceutical ingredient, wherein the pharmaceutical composition makes a transition from liquid to gel near the body temperature of a mammal These compositions may include a reversibly-gelling material, such as methylcellulose and a rheology modifier such as citrate.

Abstract: A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib.

Abstract: A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, with associated angiogenesis and fibrosis, wherein the disease or disorder is selected from the group consisting of rosacea, psoriasis, erythema multiforme, bullous pemphigoid, hereditary hemorrhagic telangiectasia, rheumatoid arthritis, atopic dermatitis, and dermal wound healing. The pharmaceutical composition includes at least one multi-kinase inhibitor selected from the group consisting of axitinib, nintedanib, and lenvatinib.

Abstract: This disclosure relates to aqueous suspension formulations of multi-target inhibitors. These formulations can be locally administered to target tissues such as eyes, prostate, that may be solved by the present disclosure are to (1) provide an injectable dosage form that allows direct delivery of a multi-target inhibitor to the proximity of the diseased tissue, (2) be compatible with the tissue of the site of administration, (3) form a drug reservoir at the administration site to allow prolonged supply of the drug to the diseased tissue, and thus reduce dosing frequency, (4) the release rate of the drug from the reservoir is such that above therapeutic level of the drug in the diseased tissue is achievable, (5) have physicochemical properties that are suitable for clinical uses, (6) be terminally sterilizable so that safety risk due to contamination of micro-organisms can be minimized, and (7) have a stability profile suitable for long term storage and distribution.

Abstract: A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat.

Abstract: A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat. The dermal fibrotic disorder is acne scars, skin scars such as keloids and hypertrophic scars, wrinkles, cellulite and dermal neoplastic fibrosis, scarring alopecia, various vasculopathy, vasculitis, burn wound healing, diabetic foot syndrome, scleroderma, arthrofibrosis, peyronie's disease, dupuytren's contracture, or adhesive capsulitis.

Abstract: A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, with associated angiogenesis and fibrosis, wherein the disease or disorder is selected from the group consisting of rosacea, psoriasis, erythema multiforme, bullous pemphigoid, hereditary hemorrhagic telangiectasia, rheumatoid arthritis, atopic dermatitis, and dermal wound healing. The pharmaceutical composition includes at least one multi-kinase inhibitor selected from the group consisting of axitinib, nintedanib, and lenvatinib.

Abstract: A method for preventing and/or treating fibrosis associated with an eye-related disease or disorder includes administering an effective amount of a multikinase inhibitor to a subject in need thereof. The multikinase inhibitor is nintedanib, lenvatinib, a combination thereof, or a salt thereof. The eye-related disease or disorder is corneal transparency, corneal scar formation, secondary cataract formation, glaucoma filtration surgery, ocular surgical procedures and implants, photorefractive keratectomy, laser in situ keratomileusis, formation and contraction of pre- and epiretinal membranes, proliferative vitreoretinopathy, subretinal fibrosis/scarring, retinal gliosis, or formation of choroidal membranes.

Abstract: A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat.

Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.

Abstract: Dosage forms of sodium {4-[5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-benzoimidazole-1-sulfonyl]-phenoxy}-acetate, and methods of use of the dosage forms are disclosed herein.

Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.

Abstract: Dosage forms of sodium {4-[5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-benzoimidazole-1-sulfonyl]-phenoxy}-acetate, and methods of use of the dosage forms are disclosed herein.

Abstract: Disclosed are methods of preventing or treating a disease or adverse condition affecting the gastrointestinal tract of a mammal which comprise orally administering to a mammal a therapeutically effective amount of a prodrug of a proton pump inhibitor and an effective amount of a trefoil family factor peptide, mucoadhesive agent, or a combination thereof. Also disclosed are compositions which are suitable for use in a pharmaceutical dosage form. These compositions comprise a prodrug of a proton pump inhibitor, and also comprise a trefoil family factor peptide, a mucoadhesive component, or a combination thereof.

Abstract: Oral dosage forms, methods of treating diseases or adverse conditions, and methods of inhibiting gastric acid secretion related to prodrugs of a proton pump inhibitor are disclosed herein. Certain embodiments relate to the membrane permeability of the proton pump inhibitor and/or the membrane permeability of the prodrug. Other embodiments relate to prodrugs comprising an acidic functional group and a sulfonyl moiety. In other embodiments, the prodrug is a carboxylic acid which comprises a phenylsulfonyl moiety. Other embodiments relate to the pH of dosage forms and dosage forms comprising salts of acidic functional groups.

Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.

Abstract: Methods including systemically, preferably orally, administering retinoid components to a human or animal to provide the desired therapeutic effect and at least one fewer drug interaction or at least one reduced drug interaction.

Abstract: Methods including orally administering retinoid components to a human or animal to provide a substantially equivalent bioavailability of the retinoid component to the human or animal without regard to the body weight of the human or animal.